Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 10,878.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,480,828 shares of the company’s stock after acquiring an additional 1,467,340 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Vir Biotechnology were worth $13,268,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of VIR. AQR Capital Management LLC raised its stake in shares of Vir Biotechnology by 2,088.4% during the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Vir Biotechnology during the 1st quarter valued at about $359,000. Goldman Sachs Group Inc. increased its stake in Vir Biotechnology by 43.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after buying an additional 225,544 shares during the period. Woodline Partners LP raised its position in shares of Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after buying an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth raised its position in shares of Vir Biotechnology by 15.3% during the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after buying an additional 2,566 shares in the last quarter. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Trading Up 5.0%

Shares of NASDAQ VIR opened at $10.04 on Friday. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $11.66. The firm has a 50-day moving average of $9.39 and a two-hundred day moving average of $8.46. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -3.21 and a beta of 1.62.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.84). Vir Biotechnology had a negative return on equity of 53.31% and a negative net margin of 638.88%.The business had revenue of ($0.03) million during the quarter, compared to analyst estimates of $55.49 million. During the same period in the prior year, the firm earned ($0.88) EPS. As a group, research analysts predict that Vir Biotechnology, Inc. will post -1.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on VIR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, April 10th. Leerink Partners boosted their target price on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Morgan Stanley upped their target price on Vir Biotechnology from $23.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, June 11th. Finally, Wall Street Zen lowered Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

Insider Buying and Selling

In related news, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the sale, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Vicki L. Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $10.05, for a total transaction of $221,100.00. Following the completion of the transaction, the director owned 1,078,391 shares in the company, valued at approximately $10,837,829.55. This trade represents a 2.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,138 shares of company stock worth $919,562. Corporate insiders own 2.90% of the company’s stock.

Vir Biotechnology Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.